Study of the Effects of Dapagliflozin 10 mg Daily on Heart Function Following Off-Pump Coronary Artery Bypass Surgery in Patients with Reduced Left Ventricular Ejection Fraction

What this Trial Is About

Researchers are studying the effects of dapagliflozin, a medication taken daily, on heart function in patients who have reduced left heart pumping and have undergone off-pump coronary artery bypass grafting OPCAB. The study focuses on measuring the right ventricular-pulmonary artery coupling by using a specific ratio called TAPSEPASP. This observational study includes 72 patients with left ventricular ejection fraction less than 50%, aiming to understand how dapagliflozin influences heart function after surgery. Participants begin dapagliflozin treatment at a dose of 10 mg once daily starting one month after their surgery. Heart function is assessed through echocardiography at three points before surgery, one month after surgery before starting dapagliflozin, and seven months after surgery following six months of dapagliflozin therapy. The study also evaluates other heart-related measures such as pulmonary artery pressure, pulmonary vascular resistance, right and left ventricular function, blood biomarkers, and quality of life. During the study, patients undergo echocardiograms and blood tests to monitor heart function and biomarkers at the specified time points. Researchers measure changes in heart function and quality of life scores between one month and seven months post-surgery. The study lasts for seven months after surgery, with close monitoring of heart measurements to evaluate the medications impact on cardiac health.

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting